Results 41 to 50 of about 156,919 (262)
Systemic sclerosis (also known as scleroderma) is a chronic fibrosing autoimmune disease with both skin and multisystem organ involvement. Scleroderma has the highest mortality among all rheumatic diseases.
Dariana-Elena Pătrîntașu +7 more
doaj +1 more source
Multiple sclerosis associated with systemic sclerosis
Multiple sclerosis (MS) has been increasingly reported in association with other autoimmune diseases not primary affected the nervous system. The coexistence of MS and systemic sclerosis (SSc) has been rarely described. We report here the case of a 46-year-old female patient with longstanding MS since the age of 26, who developed SSc 12 years later ...
Pelidou, S. H. +5 more
openaire +3 more sources
Clinical Validation of Plasma p‐217tau in Neurological Diseases
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source
Systemic Sclerosis — Scleroderma
Systemic sclerosis is a clinically heterogeneous, systemic disorder which affects the connective tissue of the skin, internal organs and the walls of blood vessels. It is characterized by alterations of the microvasculature, disturbances of the immune system and by massive deposition of collagen and other matrix substances in the connective tissue ...
openaire +4 more sources
Objective A leading cause of death among patients with scleroderma (SSc), interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M. Padilla +13 more
wiley +1 more source
Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava +48 more
wiley +1 more source
Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
Aurore Bergamasco,1 Nadine Hartmann,2 Laura Wallace,3 Patrice Verpillat41YolaRx Consultants, Paris, France; 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CO, USA ...
Bergamasco A +3 more
doaj
Systemic sclerosis, or scleroderma, is a complex medical disorder characterized by limited or diffuse skin thickening with frequent involvement of internal organs such as lungs, gastrointestinal tract, or kidneys.
Bumsoo Park +4 more
doaj +1 more source
Genetics of scleroderma: implications for personalized medicine?
Significant advances have been made in understanding the genetic basis of systemic sclerosis (scleroderma) in recent years. Can these discoveries lead to individualized monitoring and treatment?
Assassi Shervin +3 more
doaj +1 more source
Objective Ultrasound (US) has been proposed as a potential tool for assessing skin fibrosis in systemic sclerosis (SSc). However, a large‐scale comparison of US‐based assessment with histologic markers of skin fibrosis has not been reported. We evaluated US‐based skin assessments for their face validity (differentiation between involved SSc and healthy
Ruhani Desai +12 more
wiley +1 more source

